drugset
drugset / Trial / NCT00748852

Safety Study of JTT-302 in Subjects With Low HDL-C Levels

NCT00748852 ↗

Phase 2 Completed 103 enrolled Akros Pharma Inc.
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the safety of JTT-302 when administered for eight or 12 weeks in subjects with low HDL-C levels and to determine the effect of JTT-302 on lipid parameters and CETP activity and mass.

Timeline

Start
2007-01
Primary completion
2008-03
Completion
2008-03

Drugs

EvaluationDrugModalityDoseRoute
Subject JTT-302 Unknown 400 mg Oral

Indications

hyperlipidemia